Evidence map›Paper›PMID 42059893›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026

Multiomic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.

César Serrano, Andrew Elliott, David Gómez-Peregrina, Mark G Evans, Suzanne George, Margaret von Mehren, Robert G Maki, Sosipatros A Boikos, John A Charlson, Aditi Dhir and 7 more

Abstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

César Serrano *Sarcoma Translational Research Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID 0000-0003-1416-8739
Andrew Elliott *Caris Life Sciences Inc., Phoenix, Arizona.ORCID 0000-0001-8494-8031
David Gómez-PeregrinaSarcoma Translational Research Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID 0000-0003-1126-897X
Mark G EvansCaris Life Sciences Inc., Phoenix, Arizona.ORCID 0000-0001-9358-9843
Suzanne GeorgeDana-Farber Cancer Institute , Boston, Massachusetts.ORCID 0000-0002-1284-8493
Margaret von MehrenFox Chase Cancer Center , Temple University Health System, Philadelphia, Pennsylvania.ORCID 0000-0001-6158-890X
Robert G MakiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-9853-2528
Sosipatros A BoikosMedical School, Georgetown University, Washington, District of Columbia.ORCID 0000-0002-8608-6962
John A CharlsonDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.ORCID 0000-0003-2426-0029
Aditi DhirSylvester Comprehensive Cancer Center , University of Miami, Miami, Florida.ORCID 0000-0001-9974-0073
Vaia FlorouHuntsman Cancer Institute , University of Utah, Salt Lake City, Utah.ORCID 0000-0001-5558-753X
Daruka MahadevanMays Cancer Center, University of Texas Health, San Antonio, Texas.ORCID 0000-0002-7129-5593
Matthew J OberleyCaris Life Sciences Inc., Phoenix, Arizona.ORCID 0000-0001-6419-2513
George W SledgeCaris Life Sciences Inc., Phoenix, Arizona.ORCID 0000-0003-0297-0775
Gabriel TinocoDivision of Medical Oncology, The Ohio State University, Columbus, Ohio.ORCID 0000-0002-2565-6124
Richard F RiedelDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-5412-8710
Jonathan C TrentSylvester Comprehensive Cancer Center , University of Miami, Miami, Florida.ORCID 0000-0001-6169-5238

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
The Molecular Actions of Imatinib Mesylate in GISTsR01CA106588 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI GODWIN, ANDREW K., VON MEHREN, MARGARET · 2004 to 2013
$3.8M
Mechanism/activity/resistance/Gleevec/GI stromal tumors (K23M)K23CA109060 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI TRENT, JONATHAN C · 2004 to 2008
$680k
CRIS Cancer Foundation (CRIS Foundation) excellence2023_44Fundación Científica Asociación Española Contra el Cáncer (AECC) CLSEN20004SERRInstituto de Salud Carlos III (ISCIII) FI20/00275NCI NIH HHS K23 CA109060NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA106588
6 · The paper itself

Abstract

purposeGastrointestinal stromal tumor (GIST) is a genomically driven neoplasm with a genetic profile that determines the clinical course of the disease. However, currently available molecular data are limited because of the rarity of the disease and do not fully capture GIST clinical and biological heterogeneity. EXPERIMENTAL

designTo gain deeper insights into the molecular landscape of GIST, we performed a comprehensive multiomic analysis (targeted panel, whole-exome sequencing, and whole transcriptomics) in a large real-world, multicenter cohort including 1,427 cases. Pathologic review was undertaken in KIT/PDGFRA wild-type (WT) cases. Molecular findings were correlated with clinical data and insurance claims outcomes.

resultsThere is a complex spectrum of multilayered genetic events that converge in 3 GIST molecular subgroups: KIT-mutant, PDGFRA-mutant, and KIT/PDGFRA-WT. These alterations can be captured only by using next-generation sequencing technologies and are associated with clinical features, biological aggressiveness, and patient outcomes. Mutations in alternative genes, whether actionable or not, are seldom present and unlikely to contribute to tumor progression. By contrast, the cooperative effect of novel somatic copy-number alterations may be required for GIST evolution and progression, in addition to the core set of events involved in the current cytogenetic model of tumorigenesis.

conclusionsThis molecular landscape provides a broader molecular understanding of GIST and supports a widespread use of genetic profiling for patients' clinical management.

Indexed as

Biomarkers, TumorGastrointestinal NeoplasmsGastrointestinal Stromal TumorsProto-Oncogene Proteins c-kitAdultAgedCohort StudiesExome SequencingFemaleGene Expression ProfilingGenomicsHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMultiomicsBiomarkers, TumorKIT protein, humanProto-Oncogene Proteins c-kitReceptor, Platelet-Derived Growth Factor alpha

Identifiers

PMID42059893
PMCPMC13417434

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.